---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-123960"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2026-11-06T22:18:56+00:00"
generated_at: "2026-11-06T22:20:09.039781+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Quoin Q3 2026 net loss widens to ~$4.9M as QRX003 interim Phase 2/3 data meet primary endpoint

## Summary
- Q3 2026 net loss ~$4.9M vs ~$3.9M a year earlier; nine-month net loss ~$15.2M vs ~$11.5M; cash, equivalents and marketable securities ~$33.2M at Sept 30, 2026.
- Interim Phase 2/3 CL-QRX003-004 data: 4 of 6 patients (66.7%) hit the IGA primary endpoint (p=0.0087 vs alpha 0.0215); key secondary p=0.0070; no treatment-related SAEs.
- Aug 28 private placement with healthcare-focused institutions for up to ~$50.0M: ~$30.8M upfront plus up to ~$19.2M from ordinary warrant exercises.
- FDA cleared the first-ever IND for QRX003 in Peeling Skin Syndrome (July 9), then granted RPD (Sept 8) and Fast Track (Sept 22); EMA added Orphan Drug status Oct 14.
- All 20 Netherton Syndrome patients expected enrolled by end-2026 with topline in Q2 2027; first company-sponsored PSS study to start before year end.

## SEC filing metadata
- accession: 0001104659-26-123960
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2026-11-06T22:18:56+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465926123960/0001104659-26-123960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465926123960/tm2629259d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-123960
- JSON: https://secwatch.observer/filing/0001104659-26-123960.json
- Plain text: https://secwatch.observer/filing/0001104659-26-123960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.